ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Top Stocks Set to Outperform
Over the Next 1 to 3 Months.
Click for your free picks >>

Quote:

Search for Ticker

Free Membership

Search:

ARIA: Ariad Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ARIAD PHARMACEUTICALS INC (NASD)
ARIA	2.22	0.06	(2.78%)	Vol. 1,271,021	16:00 ET

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.

General Information

ARIAD PHARMA

26 Landsdowne Street Cambridge, MA 02139-4234 Phone: 617 494-0400 Fax: 617 494-8144 Web: www.ariad.com Email: investor@ariad.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/11/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	2.16
52 Week High	3.48
52 Week Low	0.72
Beta	0.98
20 Day Moving Average	2,399,149.00
Target Price Consensus	5

% Price Change
4 Week	6.93
12 Week	-2.26
YTD	154.12

% Price Change Relative to S&P 500
4 Week	5.78
12 Week	-7.86
YTD	110.31

Share Information
Shares Outstanding (millions)	108.81
Market Capitalization (millions)	235.02
Short Ratio	2.59
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.16
Current Year EPS Consensus Estimate	-0.83
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	02/11/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.20
30 Days Ago	2.20
60 Days Ago	2.00
90 Days Ago	2.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	27.59%
vs. Previous Quarter	12.50%

Sales Growth
vs. Previous Year	40.30%
vs. Previous Quarter:	2.91%

Price Ratios
Price/Book	-
Price/Cash Flow	-
Price / Sales	26.86

ROE
09/30/09	-
06/30/09	-
03/31/09	-

ROA
09/30/09	-104.43
06/30/09	-104.05
03/31/09	-94.75

Current Ratio
09/30/09	-
06/30/09	1.57
03/31/09	1.84

Quick Ratio
09/30/09	-
06/30/09	1.48
03/31/09	1.73

Operating Margin
09/30/09	-900.33
06/30/09	-958.84
03/31/09	-992.07

Net Margin
09/30/09	-900.23
06/30/09	-958.80
03/31/09	-991.99

Pre-Tax Margin
09/30/09	-900.23
06/30/09	-958.80
03/31/09	-991.99

Book Value
09/30/09	-0.66
06/30/09	-1.02
03/31/09	-0.79

Inventory Turnover
09/30/09	-
06/30/09	0.00
03/31/09	0.00

Debt-to-Equity
09/30/09	-
06/30/09	-0.13
03/31/09	-0.16

Debt to Capital
09/30/09	-
06/30/09	-
03/31/09	-


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research